Doubts cast over effectiveness of bone marrow treatment for heart failure

   Mar 25, 4:15 pm

Washington, Mar 25 (ANI): Using patient's bone marrow cells for treating chronic ischemic heart failure did not result in improvement on most measures of heart function, a new study has revealed.

Cell therapy has emerged as an innovative approach for treating patients with advanced ischemic heart disease, including those with heart failure.

"In patients with ischemic heart disease and heart failure, treatment with autologous [derived from the same individual] bone marrow mononuclear cells (BMCs) has demonstrated safety and has suggested efficacy. None of the clinical trials performed to date, however, have been powered to evaluate specific efficacy measures," according to background information in the article.

Emerson C. Perin, M.D., Ph.D., of the Texas Heart Institute and St. Luke's Episcopal Hospital, Houston and colleagues conducted a study to examine the effect of transendocardial administration (use of a special catheter and injection procedure to deliver stem cells to the heart muscle) of BMCs to patients with chronic ischemic heart disease and left ventricular (LV) dysfunction with heart failure and/or angina.

The patients in the phase 2 randomized trial were receiving maximal medical therapy at 5 National Heart, Lung, and Blood Institute-sponsored Cardiovascular Cell Therapy Research Network (CCTRN) sites between April 2009 and April 2011.

Patients were randomized to receive transendocardial injection of BMCs or placebo.

The primary outcomes measured for the study, assessed at 6 months, were changes in left ventricular end-systolic volume (LVESV) assessed by echocardiography, maximal oxygen consumption, and reversibility of perfusion (blood flow) defect on single-photon emission tomography (SPECT).

Of 153 patients who provided consent, a total of 92 (82 men; average age: 63 years) were randomized (n = 61 in BMC group and n = 31 in placebo group).

Analysis of data indicated no statistically significant differences between the groups for the primary end points of changes in LVESV index, maximal oxygen consumption, and reversible defect.

There were also no differences in any of the secondary outcomes, including percent myocardial defect, total defect size, fixed defect size, regional wall motion (the movement of the wall of the heart during contraction), and clinical improvement.

In an exploratory analysis, the researchers did find that when LVEF was assessed, patients age 62 years or younger showed a statistically significant effect of therapy.

Patients in the BMC group demonstrated an average increase in LVEF of 3.1 percent from baseline to 6 months, whereas patients in the placebo group showed a decrease of -1.6 percent.

"In the largest study to date of autologous BMC therapy in patients with chronic ischemic heart disease and LV dysfunction, we found no effect of therapy on prespecified end points," the authors wrote.

"Further exploratory analysis showed a significant improvement in LVEF associated with treatment. Our findings provide evidence for further studies to determine the relationship between the composition and function of bone marrow product and clinical end points.

"Understanding these relationships will improve the design and interpretation of future studies of cardiac cell therapy," the authors added.

The study has been published in JAMA. (ANI)

Asteroid that made dinosaurs extinct almost wiped off mammals too Dec 18, 1:17 pm
Washington, Dec 18 (ANI): A new study has shed light on an asteroid that wiped out dinosaurs may have wiped out mammals as well.
Full Story
Science community happy over successful launch of GSLV Mark-III Dec 18, 1:14 pm
New Delhi, Dec. 18 (ANI): Senior scientist and SPACE India director C B Devgun on Thursday expressed happiness over the successful launch of Geosynchronous Satellite Launch Vehicle (GSLV) Mark-III, adding that this was the first test done without the cryogenic engine and that the new module CREW that has been crafted to ensure the safe arrival of astronauts back to earth, had been tested successfully.
Full Story
Substance from broccoli can help ward off premature ageing Dec 18, 1:14 pm
Washington, Dec 18 (ANI): A team of scientists has revealed that Hutchinson-Gilford Progeria Syndrome (HGPS) related defects can be reduced with the help of a substance found in broccoli.
Full Story
Longer we take to decide, the less accurate and confident we get Dec 18, 12:28 pm
Washington, Dec 18 (ANI): A team of neuroscientists has found that the longer people take to decide, the less accurate and confident they are.
Full Story
Comments

LATEST STORIES
TOP VIDEO STORIES
PHOTO GALLERY